StageLoan | Alive
Last Raised$250K | 3 yrs ago
About Mercator MedSystems
Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.
Missing: Mercator MedSystems's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Mercator MedSystems's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Mercator MedSystems
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Mercator MedSystems is included in 5 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Mercator MedSystems Patents
Mercator MedSystems has filed 42 patents.
The 3 most popular patent topics include:
- Vascular diseases
Drug delivery devices, Dosage forms, Medical equipment, Catheters, Medical treatments
Drug delivery devices, Dosage forms, Medical equipment, Catheters, Medical treatments
Latest Mercator MedSystems News
Jun 7, 2022
| DelveInsight News provided by Share this article Share this article The critical limb ischemia market is expected to expand with a rise in prevalence and the expected entry of emerging therapies into the 7MM markets. LAS VEGAS, June 7, 2022 /PRNewswire/ -- DelveInsight's critical limb ischemia market insights report includes a comprehensive understanding of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2018 to 2030, segmented into 7MM (the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Key Takeaways from the Critical Limb Ischemia Market According to DelveInsight estimates, the Critical Limb Ischemia market size in the 7MM was USD 1,519 million in 2020. As per analysis, the total critical limb ischemia diagnosed prevalent population in the 7MM was approximately 2 million in 2020. Key critical limb ischemia companies such as Boston Scientific Corporation, AnGes, Inc., Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Inc, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, Inc., New Beta Innovation Limited, BioGenCell Ltd., Abbott Medical Devices, and others are developing novel drugs and technologies/devices, which can be available in the critical limb ischemia market in the upcoming years. The critical limb ischemia therapies/technologies/devices in the pipeline include REX-001, Temsirolimus Adventitial Delivery, Collategene, ACP-01, Honedra (CLBS12), RJX (Rejuveinix), YQ23, BGC101, Esprit BTK Device, and others. The increase in the critical limb ischemia market size directly impacts the increasing prevalent population of critical limb ischemia patients in the 7MM. Discover more about therapies that are set to grab major critical limb ischemia market share at critical limb ischemia market landscape Critical Limb Ischemia Critical limb ischemia is a clinical syndrome characterized by ischemic pain at rest and tissue loss, such as nonhealing ulcers or gangrene, caused by lower limb peripheral arterial disease (PAD). Critical limb ischemia is the final stage of PAD, and macrovascular lesions cause a decrease in distal perfusion. This disease drastically impairs nutrient blood flow to tissues and microcirculation exchange. Rutherford has traditionally characterized critical limb ischemia as rest pain (class 4), tissue loss (class 5), and gangrene (class 6). Rest discomfort is classified as class 3 in the Fontaine classification, and tissue loss or gangrene is classified as class 4 in the Fontaine classification. The threatened critical limb ischemia classification system was recently developed by the Society for Vascular Surgery Lower Extremity Guidelines Committee: Risk stratification based on wound, ischemia, and foot infection (WIfI). The critical limb ischemia life expectancy is around 1.23 years for men and 2.7 years for women. The most noticeable critical limb ischemia symptoms are ischemic rest pain — extreme pain in the legs and feet when a person is not moving or nonhealing sores on the feet or legs. Other critical limb ischemia symptoms include an absent or decreased pulse in the legs or feet, open sores, skin infections or nonhealing ulcers, toenail thickening, dry gangrene, shiny, smooth, dry skin of the legs or feet, and pain or numbness in the feet; other factors such as age, smoking, diabetes, high cholesterol, family history, etc. also contribute. Physical examination and noninvasive hemodynamic testing (ankle-brachial index [ABI]/ankle pressure [AP], toe-brachial index [TBI]/toe pressure [TP], imaging of vascular anatomy, duplex ultrasound imaging [DUS], computed tomography angiography [CTA], and others) can be used for critical limb ischemia diagnosis. Critical Limb Ischemia Epidemiology Segmentation Among EU5 countries, Germany had the highest critical limb ischemia diagnosed prevalence in 2020. The critical limb ischemia market report offers epidemiological analysis for the study period 2018–2030 in the 7MM segmented into: Total diagnosed prevalent cases of critical limb ischemia Age-specific diagnosed prevalent cases of critical limb ischemia Severity-specific diagnosed prevalent cases of critical limb ischemia Diagnosed prevalent cases of no-option critical limb ischemia Download the report to understand which factors are driving critical limb ischemia epidemiology trends at critical limb ischemia epidemiological insights Critical Limb Ischemia Treatment Market The basic aim of Critical Limb Ischemia treatment is pain relief, trophic lesion healing, avoiding high-level amputations, improving limb functionality and quality of life, and improving medium-term survival. These objectives call for an interdisciplinary approach. Revascularization is the most common and effective critical limb ischemia treatment option. Other approaches include the administration of analgesics, the treatment of infections, and the optimization of cardiac and pulmonary function. Patients with critical limb ischemia require monitoring and therapy for cardiovascular risk factors as much as any other patient with PAD. When revascularizing operations are not possible or have proven unsuccessful, prostanoids are utilized. Cell and gene therapies are gaining popularity as critical limb ischemia treatments for patients ineligible for endovascular or surgical revascularization. Several regeneration treatments, including angiogenic recombinant proteins, gene therapy, cell-based therapies (including stem or progenitor cells), and chemokines, have been studied in patients with PAD and nonrevascularizable critical limb ischemia. Collategene (HGF plasmid) is the only approved critical limb ischemia treatment in Japan. The company also intends to penetrate the US critical limb ischemia market. Furthermore, many cell therapies are being developed to target the population that is not appropriate for revascularization or has poor results following revascularization. To know about more Critical Limb Ischemia management, visit at critical limb ischemia guidelines Critical Limb Ischemia Pipeline Therapies/Technologies/Devices and Key Companies REX-001: Ixaka Ltd (formerly Rexgenero) Temsirolimus Adventitial Delivery: Mercator MedSystems, Inc. Collategene: Anges and Mitsubishi Tanabe Pharma ACP-01: Hemostemix Inc. YQ23: New Beta Innovation Limited BGC101: BioGenCell Ltd. The rising prevalence of diabetes due to an aging global population will boost the critical limb ischemia treatment options, resulting in critical limb ischemia market growth. Moreover, companies are actively developing critical limb ischemia drugs to address the disease's unmet requirements, despite the disease's low visibility and complexity. Except in Japan, there are no authorized pharmaceutical critical limb ischemia treatment alternatives, creating tremendous potential for investment and research for innovative drugs along with less competition. The present unmet need of the critical limb ischemia market is medications that are safer and more effective in providing an optimal cure. However, some factors restrain the critical limb ischemia market growth. The disease is being underdiagnosed and undertreated, resulting in greater morbidity, death, and costs. Lack of awareness and other similar diseases challenge the critical limb ischemia market's growth. Pricing and reimbursement rules that are strictly enforced also limit the growth of the critical limb ischemia market along with the failure of drugs in clinical development. Moreover, the availability of surgical procedures may make it difficult for innovative treatments to get a foothold. Scope of the Critical Limb Ischemia Market Report Study Period: 2018–2030 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Critical Limb Ischemia Companies: Boston Scientific Corporation, AnGes, Inc, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Inc, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, Inc., New Beta Innovation Limited, BioGenCell Ltd., Abbott Medical Devices, and others Key Critical Limb Ischemia Therapies/Technologies/Devices: REX-001, Temsirolimus Adventitial Delivery, Collategene, ACP-01, Honedra (CLBS12), RJX (Rejuveinix), YQ23, BGC101, Esprit BTK Device, and others Therapeutic Assessment: Critical Limb Ischemia current marketed and emerging therapies Critical Limb Ischemia Market Dynamics: Critical Limb Ischemia market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Critical Limb Ischemia Market Access and Reimbursement Discover more about the future critical limb ischemia market share of treatment therapies at critical limb ischemia treatment market Table of Contents Peripheral Arterial Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, and market barriers. The key companies are NovoNordisk, Takeda, Mercator MedSystems, Inc., among others. Other Trending Reports "Degenerative Disc Disease (DDD) Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the degenerative disc disease market size, share, and trends in the 7MM. Some of the key companies in the degenerative disc disease market are DiscGenics, Kuros Biosciences, Mesoblast, Ankasa Therapeutics, and others. "Periodontal Disease Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the periodontal disease market size, share, and trends in the 7MM. Some of the key companies in the periodontal disease market are D and D Pharmatech, Amyndas Pharmaceuticals, AngioLab, Denteric, Dexcel Pharma Technologies, Yuhan Corporation, and others. "IgG4-Related Disease Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the IgG4-related disease market size, share, and trends in 7MM. Some of the key companies in the IgG4-related disease market are Bristol-Myers Squibb, Xencor, Principia Biopharma, Viela Bio, Horizon Therapeutics, and others. "Nicotine Addiction Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the nicotine addiction market size, share, and trends in the 7MM. Some of the key companies in the nicotine addiction therapeutics market include Axsome Therapeutics, Achieve Life Sciences, Novo Nordisk, and others. "Hairy Cell Leukemia (HCL) Market" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the hairy cell leukemia (HCL) market size, share, and trends in the 7MM. Some of the key companies in the hairy cell leukemia (HCL) therapeutics market include AstraZeneca, Janssen, Merck, Pharmacyclics, Johnson and Johnson, Roche, Innate Pharma, and others. "Hypereosinophilic Syndrome Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the hypereosinophilic syndrome market size, share, and trends in 7MM. Some key companies in the hypereosinophilic syndrome market include AstraZeneca, GlaxoSmithKline, Knopp Biosciences, and others. Related Healthcare Blogs
Mercator MedSystems Frequently Asked Questions (FAQ)
When was Mercator MedSystems founded?
Mercator MedSystems was founded in 1999.
Where is Mercator MedSystems's headquarters?
Mercator MedSystems's headquarters is located at 1900 Powell Street, Emeryville.
What is Mercator MedSystems's latest funding round?
Mercator MedSystems's latest funding round is Loan.
How much did Mercator MedSystems raise?
Mercator MedSystems raised a total of $23.33M.
Who are the investors of Mercator MedSystems?
Investors of Mercator MedSystems include Paycheck Protection Program, Crocker Capital, Aphelion Capital, Life Ventures, Salubris Pharmaceuticals and 6 more.
Who are Mercator MedSystems's competitors?
Competitors of Mercator MedSystems include Velico Medical, Intrinsic Therapeutics, AlterG, Cardiva Medical, Verax Biomedical, INRange Systems, TransMedics, Light Sciences Oncology, Keystone Dental, Celsense and 53 more.
Compare Mercator MedSystems to Competitors
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
AlterG builds technology for physical rehabilitation, training and wellness with the goal of enabling people to sustain healthy and active lives through mobility. The company's products, the Anti-Gravity Treadmills and the AlterG Bionic Leg, are designed to enhance personal mobility and wellness. Its Anti-Gravity Treadmills use Differential Air Pressure (DAP) technology, originally developed at NASA, to unweight patients to as low as 20% of their body weight, enabling them to walk or run with reduced impact. The Bionic Leg, designed for patients with neurological and orthopedic gait disorders, is a robotic assistive device that is activated by patient initiated movement and provides stability and assistance for a full range of mobility training.
Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration
Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.
Carticept Medical is a medical device-developing company. It provides solutions for patients with osteoarthritis and cartilage damage. It offers products to address the shortcomings of the current conservative and surgical treatment options for osteoarthritis and cartilage injuries such as ultrasound products, computer-controlled infusion systems, and a medical device to replace and repair worn and damaged cartilage. Carticept Medical was formerly known as Windward Medical. The company was founded in 2005 and is based in Alpharetta, Georgia.
20/10 PERFECT VISION OPERATIONS GmbH of Heidelberg, Germany, develops, manufactures and markets technologies for raising refractive surgery well beyond current expectations. The company's expertise lies in diagnostic as well as therapeutic technologies. 20/10 PERFECT VISION's FEMTEC femtosecond laser workstation is set to revolutionize the ophthalmic surgery market, while keeping ease-of-use and patient safety as primary objectives.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.